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Abstract
Background: The availability of non-rodent animal models for human cirrhosis is limited. We
investigated whether privately-owned dogs (Canis familiaris) are potential model animals for liver
disease focusing on regenerative pathways. Several forms of canine hepatitis were examined: Acute
Hepatitis (AH), Chronic Hepatitis (CH), Lobular Dissecting Hepatitis (LDH, a specific form of
micronodulair cirrhosis), and Cirrhosis (CIRR). Canine cirrhotic samples were compared to human
liver samples from cirrhotic stages of alcoholic liver disease (hALC) and chronic hepatitis C
infection (hHC).
Results: Canine specific mRNA expression of the regenerative hepatocyte growth factor (HGF)
signaling pathway and relevant down-stream pathways were measured by semi-quantitative PCR
and Western blot (STAT3, PKB, ERK1/2, and p38-MAPK). In all canine groups, levels of c-MET
mRNA (proto-oncogenic receptor for HGF) were significantly decreased (p < 0.05). Surprisingly,
ERK1/2 and p38-MAPK were increased in CH and LDH. In the human liver samples Western
blotting indicated a high homology of down-stream pathways between different etiologies (hALC
and hHC). Similarly activated pathways were found in CIRR, hALC, and hHC.
Conclusion: In canine hepatitis and cirrhosis the major regenerative downstream pathways were
activated. Signaling pathways are similarly activated in human cirrhotic liver samples, irrespective of
the differences in etiology in the human samples (alcohol abuse and HCV-infection). Therefore,
canine hepatitis and cirrhosis could be an important clinical model to evaluate novel interventions
prior to human clinical trials.
Background
Chronic hepatitis (CH) and end-stage cirrhosis (CIRR) are
an increasing medical problem, affecting over 5% of the
world population [1,2]. The best-studied animal model
for these liver diseases is tetracarbon-induced fibrotic liver
diseases inflicted in rats [3]. Many more models have been
devised to mimic liver diseases in man; the time-course of
the development however, is not always comparable to
the human situation [4-8]. Furthermore, the variability in
the affected human population regarding, sex, age, social
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factors, eating- and drinking behavior, body weight etc. is
not fully covered in standardized laboratory conditions.
Dogs have liver diseases which are clinically highly com-
parable with the human counterparts and both species
have a high resemblance at the genetic level [9,10]. In con-
trast to rodent models, hepatitis in these dogs is not delib-
erately induced. Previous studies already showed a high
resemblance between man and dogs in the formation of
fibrosis during liver diseases [11]. Furthermore dogs share
many years in close proximity of humans exposing them
to the same environmental and biological stresses.
Recently, detailed clinical and histological diagnostic
standards have been published for all liver diseases of
dogs [12]. Corroborating the histological similarities
between human and dogs, examples are provided in Fig-
ure 1. Taken together, these similarities suggest the dog as
a model animal for liver diseases in man [13].
Liver regeneration is a complex interplay of different fac-
tors [14]. One of the main growth factors identified in
liver regeneration is Hepatocyte Growth Factor (HGF).
HGF activates the proto-oncogenic receptor tyrosine
kinase c-MET and subsequent down-stream pathways,
including the anti-apoptotic protein kinase-B (PKB/Akt)
cascade, the proliferative MAP-kinase pathway (ERK1/2
and p38MAPK), and the STAT3 signaling (signal transduc-
ers and activators of transcription) [15-17]. At present, a
comparison between these regeneration signal transduc-
tion pathways in human and canine livers is missing,
hampering the application of dogs as (pre-) clinical
model animals for human medicine.
We have analyzed HGF-mediated regeneration signaling
in canine samples from dogs with Acute Hepatitis (AH),
Chronic Hepatitis (CH), and Lobular Dissecting Hepatitis
(LDH, a specific form of micronodulair cirrhosis similar
to neonatal hepatitis in human hepatology) [18,19], and
CIRR. The cirrhotic samples were compared to two
human cirrhotic diseases with different etiologies; HCV-
induced (hHC) and alcohol-induced (hALC). This study
will elucidate the potential of (non-experimental) dogs to
bridge between toxin-induced rodent models and human
clinical situation.
Results
HGF/c-MET signaling pathways involved in liver 
regeneration in dogs with AH, CH, CIRR, and LDH
Statistically significant differences (ANOVA) were identi-
fied in the expression of mRNA encoding HGF (P < .001)
and c-MET (P < .001). Towards healthy control samples
HGF mRNA levels were significantly induced in CH, LDH,
and CIRR, three-, five-, and five-fold, respectively (Figure
2A). In AH, HGF mRNA levels remained unchanged
toward healthy control. Western blot analysis on HGF
Examples of histological samples (HE) from canine and  human liver diseases Figure 1
Examples of histological samples (HE) from canine 
and human liver diseases. CANINE ACUTE HEPATITIS: 
Marked infiltration of mononuclear and granulocytic inflam-
matory cells and focal necrosis. CANINE CHRONIC HEPA-
TITIS: Small fibrous septum with interface hepatitis as well as 
lobular hepatitis; several apoptotic bodies. CANINE LOBU-
LAR DISSECTING HEPATITIS: Lobular dissection by fibrob-
lasts and ductular proliferation and a slight inflammatory 
infiltrate. CANINE CIRRHOSIS: Broad fibrous septum with 
ductular proliferation and a marked inflammatory infiltrate 
with interface hepatitis. HUMAN ACUTE HEPATITIS: 
Marked infiltration of mononuclear and some granulocytic 
inflammatory cells and some apoptotic bodies. HUMAN 
CHRONIC HEPATITIS: Fibrous septum with some ductular 
proliferation and slight interface hepatitis. HUMAN MICRO-
NODULAR CIRRHOSIS: Dissection of the parenchyma by 
small fibrous septa, slight ductular proliferation and inflamma-
tion; hepatocytic ballooning, Mallory bodies, and apoptosis. 
HUMAN CIRRHOSIS: Broad fibrous septum with ductular 
proliferation and a marked inflammatory infiltrate with inter-
face hepatitis.Comparative Hepatology 2007, 6:8 http://www.comparative-hepatology.com/content/6/1/8
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protein showed the presence of a HGF band (80 kDa) in
all canine samples. There is a clear quantitative correlation
between HGF protein and mRNA levels, as both HGF
mRNA and protein levels are increased in CH, LDH, and
CIRR. The c-MET mRNA levels in all groups were signifi-
cantly decreased towards control, with a maximum four-
fold reduction in AH (Figure 2B). Total c-MET protein lev-
els are similarly reduced as the mRNA levels. Analysis on
phosphorylated c-MET showed an immuno-reactive band
in CH, LDH, and CIRR, which was almost absent in AH.
Western blot analysis on STAT3, PKB/Akt, ERK1/2, and 
p38MAPK in canine liver homogenates
In Figure 3 important downstream signaling proteins of
HGF/c-MET (STAT3, PKB/Akt, ERK1/2, and p38-MAPK)
are depicted. The total STAT3 was detected as an immuno-
reactive 86 kDa band in all hepatic diseases, with slightly
lower expression in CH, LDH, and CIRR. Tyrosine (Tyr)-
phosphorylated STAT3 was strongly reduced in AH and
was increased in LDH. Healthy controls, CH, and CIRR
groups had comparable levels of Tyr-phosphorylated
STAT3. Serine (Ser)-phosphorylated STAT3 was slightly
decreased in CIRR. PKB/Akt plays a pivotal role during
regeneration and growth. Total PKB/Akt was detected in
all hepatic diseases as a single 60 kDa protein. Threonine
(Thr)-phosphorylated PKB/Akt was less present in AH and
CIRR, whereas CH and LDH showed no apparent quanti-
tative differences toward healthy controls. Analysis of
total ERK1/2 (42/44 kDa), a principle kinase in growth
factor signaling, showed a slight reduction in AH, and
moderate increases in CH, LDH, and CIRR. The phospho-
rylated form threonine/tyrosine (Thr/Tyr)-phosphor-
ylated ERK1/2 was strongly increased in CH and LDH. A
similar effect can be seen in p38-MAPK, an increased
expression of total p38-MAPK in CH, LDH, and CIRR and
decreased levels in AH. The threonine/tyrosine (Thr/Tyr)-
phosphorylated p38-MAPK form is increased in CH, LDH,
and CIRR.
Western blot analysis on human cirrhotic explant samples 
after alcohol abuse (hALC) and after hepatitis C virus 
infection (hHC)
Western blot analysis on HGF in hALC and hHC samples
showed a detectable 80 kDa HGF in all samples with
minor quantitative differences (Figure 4). The 145 kDa c-
MET was also detected in all samples. The phosphorylated
form of c-MET (Tyr) was detected in all samples. Total
PKB/Akt was detected in all samples. The phosphorylated
PKB (Thr) indicated moderate to high levels in most cir-
rhotic samples. Total STAT3 was detectable in all individ-
ual samples. STAT3 (Tyr) was detected in all groups
although two samples in the hHC group were less phos-
phorylated. In general the serine phosphorylated STAT3 is
lower in the hALC group compared to the hHC group.
Total ERK1/2 was detected in all samples with no appar-
ent quantitative differences. Phosphorylated ERK1/2 was
detectable in all samples with different degrees of phos-
phorylation. Both total p38MAPK as well as the serine
phosphorylated form was detected in all samples with no
apparent quantitative differences.
Discussion
To investigate if hepatic regenerative signal transduction
pathways are similarly affected in liver diseases between
Quantitative Real-Time PCR of genes involved in regenera- tion and growth Figure 2
Quantitative Real-Time PCR of genes involved in 
regeneration and growth. Expression analysis of acute 
hepatitis (AH), chronic hepatitis (CH), lobular dissecting hep-
atitis (LDH), cirrhotic samples (CIRR). HGF expression and 
detection of the 80 kDa HGF protein is shown in (A). c-MET 
gene expression and detection of c-MET including phosphor-
ylated (Tyr) form is shown in (B). Relative gene expression 
data represent mean + SE. A Kolmogorov-Smirnov test was 
performed to establish a normal distribution and a Levenes 
test for the homogeneity of variances. All samples included in 
this study were normally distributed. The statistical signifi-
cance of differences between diseased and control animals 
was determined by using the two-sided Dunnetts post-test 
analysis. A P-value < 0.05 was considered statistically signifi-
cant. Analysis was performed using SPSS software (SPSS Ben-
elux BV, Gorinchem, the Netherlands).
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man and dogs, the expression of HGF and c-MET was
measured. Furthermore, Western blot analysis was used to
show (de)activation of important signaling pathways of
liver regeneration. This provided insight into major regen-
eration pathways in AH, CH, LDH, CIRR. A comparison
between canine cirrhosis and human cirrhotic samples
with different etiologies provided additional information
on the suitability of the canine-model.
The increased mRNA levels of HGF and the decreased lev-
els of c-MET mRNA in fibrotic canine diseases (CH, LDH,
and CIRR), were in line with publications from human
samples [20]. Together this suggests that HGF-mediated
regeneration in human cirrhosis is similarly affected in
canine CH, LDH, and CIRR. The reduced c-MET protein
levels indicate a utilization of c-MET which is degraded
through endocytosis after phosphorylation. Intracellular
degradation is dependent on the interaction with Cbl
ubiquitin ligases [21]. Semi-quantitative hepatocyte pro-
liferation studies on canine samples with a Ki67 antibody
indicate a moderate hepatocyte proliferation in CH;
whereas cirrhotic samples (CIRR and LDH) as well as
healthy samples are virtually negative (data not shown).
Similar results have been described in human chronic and
cirrhotic liver samples, irrespective of the etiology [22,23].
This indicates the ability of hepatocytes to proliferate after
c-MET activation in more chronic stages while cirrhotic
samples do not complete the cell-cycle of which the cause
remains to be elucidated.
To further substantiate the molecular comparison
between human and canine fibrotic livers the activation
status of HGF/c-MET downstream signaling components
involved in regeneration was analyzed. HCV cirrhotic
samples had high levels of Ser-phosphorylated STAT3
compared to alcohol induced cirrhotic samples. This
HCV-induced up regulation of STAT3 phosphorylation
was shown before in man and rodent models in vivo as
well as in vitro studies on cell-lines [24,25]. In other stud-
ies the levels of STAT phosphorylation indicated phos-
phorylated STAT3 protein in HCV affected cirrhotic livers
compared to primary biliary cirrhotic samples and
healthy tissue [26]. In the canine samples including the
healthy control biopsies STAT3-Ser phosphorylation was
strongly present. The levels of STAT3-Tyr phosphorylation
were the lowest in AH and strongest in LDH. As the
amount of STAT3-Tyr phosphorylation indicates the DNA
binding capacity of the protein, the pathways seems to be
activated in fibrotic diseases and not in acute hepatitis.
Next to STAT3 phosphorylation, HCV induces ERK1/2
phosphorylation [27]. In the canine samples, an up regu-
lation of the levels of phosphorylated ERK1/2 was
observed in CH and LDH. Finally, the increase in
p38MAPK phosphorylation as observed in CH, LDH, and
CIRR has been described in fibrotic tissues in man [28]. In
general, HGF/c-MET downstream signaling in CH, LDH,
and CIRR is to a high degree comparable with the molec-
ular data obtained from human clinical samples.
Western blot analysis of human liver homogenates of several  diseases (n = 6) Figure 4
Western blot analysis of human liver homogenates of 
several diseases (n = 6). Samples 1 to 5 represent individ-
ual alcoholic cirrhosis (hALC) shown in (A), samples 6 to 9 
represent individual hepatitis C induced cirrhotic samples 
(hHC) shown in (B). Beta-actin was used as a loading control.
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Western blot analysis of canine liver homogenates of several  diseases (n = 6) Figure 3
Western blot analysis of canine liver homogenates of 
several diseases (n = 6). Western blot analysis of pooled 
canine liver homogenates in acute hepatitis (AH), chronic 
hepatitis (CH), lobular dissecting hepatitis (LDH), cirrhotic 
samples (CIRR). Detection of the 86 kDa STAT3 protein (A), 
detection of the 60 kDa PKB protein (B), detection of the 44/
42 kDa ERK 1/2 protein shown in (C), and detection of the 
p38-MAPK protein shown in (D). Beta-actin was used as a 
loading control.
1:        Control
2:        Acute Hepatitis
3:        Chronic Hepatitis
4:        Lobular Dissecting 
Hepatitis
5:        Cirrhosis
Lane Samples 1        2         3        4        5
p-PKB (Thr)
Beta-actin
PKB
p-STAT3 (Tyr)
p-STAT3 (Ser)
STAT3
p-ERK1/2 (Thr/Tyr)
ERK1/2 
44 kDa
42 kDa 
44 kDa
42 kDa 
42 kDa 
86 kDa 
86 kDa 
86 kDa 
60 kDa 
60 kDa 
P38-MAPK (Ser) 
P38-MAPK 
37 kDa 
37 kDa 
A
B
C
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Surgical animal models for liver regeneration, such as par-
tial hepatectomy (PH), represent an over-simplification
by the absence of inflammation or overperfusion; further-
more, all hepatocytes are stimulated by PH to enter the G1
phase simultaneously. Toxic models induced by dimeth-
ylnitrosamine, CCl4, acetominophen, or thioacetamide
can represent chronic as well as acute/fulminant hepatitis
[29-31]. Toxic models are better clinical models as hepa-
totoxins can be used to selectively induce centrolobular
and periportal necrotic lesions and thus mimic clinical
liver diseases. However, toxin-induced models do not rep-
resent the full range of changes seen in human liver dis-
eases [32].
Comparison between canine and human diseases was
obtained by using cirrhotic human samples derived from
alcohol abuse or hepatitis C infection, two of the most
common causes of hepatitis in the Western world [33,34].
As in humans, chronic hepatitis in dogs is associated with
progressive fibrosis, reduction in liver size and regenera-
tion, and finally disruption of the liver architecture (cir-
rhosis), which may cause portal hypertension, ascites, and
portosystemic encephalopathy [35]. Although histologi-
cally highly comparable to their human counterparts, the
etiology of canine hepatitis is largely unknown [36]. How-
ever, human samples (hALC and hHC) showed the same
degree of activation in the signal transduction pathways,
irrespective of the different underlying etiology. There-
fore, despite unknown etiology in dogs the underlying
mechanisms are similarly activated.
Conclusion
This study is the first to measure expression profiles of cru-
cial pathways of liver regeneration in canine liver diseases
in comparison with man. Previously, a high similarity of
affected fibrotic pathways between human- and canine-
liver diseases was found [11]. Combining these measure-
ments on fibrotic- and regenerative-signaling pathways,
privately owned dogs may help to fill in the gap between
toxin-induced rodent models and human diseases. Fur-
thermore, this study provides the basis to analyze more
acute forms of hepatitis such as (sub)acute hepatitis in
dog. Taken together, these results indicated that CH, LDH,
and CIRR are suitable spontaneous large animal models
to evaluate the clinical application of therapies such as cell
transplantation or the administration of growth factors.
Methods
Animals
All samples were obtained from privately owned canines
of different breeds referred to our veterinary clinic. All
procedures were approved by Utrecht University's Ethical
Committee, as required under Dutch legislation. Each dis-
ease group (n = 11 dogs) was compared to age-matched
healthy control dogs (n = 12), without clinical signs of
hepatitis or other disease (histopathology did not reveal
any abnormalities). Liver biopsies were obtained (ultra-
sound-guided) from all dogs under local anesthesia with
a true cut 14G biopsy needle, preceded by ultrasono-
graphic evaluation of the liver to exclude non-homogene-
ous hepatic changes. Two formalin-fixed biopsies were
embedded in paraffin, sliced, and stained with hematoxy-
lin and eosin-, van Gieson-, and reticulin-stain according
to Gordon and Sweet. All histological examinations were
performed by one experienced, certified veterinary pathol-
ogist. Two other biopsies were snap-frozen and stored at -
70°C until molecular analysis.
Human patients
All liver samples were obtained from surgical patients
transplanted at the Department of Abdominal Transplan-
tation in the University Hospital Leuven, Leuven, Bel-
gium. The procedures were approved by Leuven
University's Ethical Committee, as required under Belgian
legislation. Human explant samples were collected
directly after surgery and immediately snap-frozen. All
patients, predominantly male, were presented with micro-
nodular cirrhosis. The Alcoholic Cirrhosis (hALC) group
contained five patients (n = 5) characterized by cirrhosis
with neutrophil infiltrations, alcohol related morpholog-
ical changes (hepatocyte ballooning, Mallory bodies,
necrosis), and in some cases steatosis and increased iron
deposition. The Hepatitis C (hHC) group contained four
patients (n = 4) characterized by cirrhosis with neutrophil
infiltrations, lymphoid follicles and aggregates. All cases
were presented with hepatocyte decay, apoptosis/necro-
sis, regeneration, and fibrosis.
Quantitative PCR
Quantitative real-time PCR (Q-PCR) was performed on
HGF and c-MET. The abundance of mRNA was deter-
mined by reverse transcription followed by real-time
quantitative PCR using appropriate primers (Table 1), as
described previously [37]. For each experimental sample,
two endogenous reference genes (GAPDH and HPRT)
were included. The use of two reference genes is sufficient
for reliable data [38]. Results were normalized according
to the average amount of the endogenous references. The
relative gene-expression of each gene-product was used as
the basis for all comparisons. The results were assessed for
normality and homogeneity of variances using, respec-
tively, the Kolmogorov Smirnoff and the Levene tests. The
data were normally distributed and variances complied;
therefore differences between means were determined by
One Way Analysis of Variance (ANOVA) followed by the
(2-sided) Dunnett post-test analysis of all groups towards
control (healthy) samples. A P-value < 0.05 indicated sig-
nificant changes.Comparative Hepatology 2007, 6:8 http://www.comparative-hepatology.com/content/6/1/8
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Immunoblot analysis
Twenty micrograms of pooled protein extracts (n = 6 dogs
per group, randomly chosen) was separated by SDS-
PAGE, and transferred to a Hybond ECL nitrocellulose
membrane (Amersham-Biosciences, Cleveland, OH). The
procedure for immunodetection was based on an ECL-
Western blot analysis system, as previously described [39].
Primary antibodies are depicted in Table 2. Densitometric
analysis was performed with a Geldoc2000 system with
QuantityOne 4.3.0 software (Biorad). Human samples
(protein load twenty micrograms) were analyzed sepa-
rately; the immunoblot analysis was the same as for the
dog protein extracts.
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Table 2: Primary Antibodies used in Western blot experiments
Antibody Product size (kDa) Dilution Supplier
Goat anti-human HGF 80 1:1,000 Santa Cruz
Goat anti-human c-MET 145 1:1,000 Santa Cruz
Rabbit anti-human c-MET (Tyr1230/1234/1235) 169 1:1,000 Abcam
Rabbit anti-human/dog STAT3 86 1:2,500 BD Biosciences
Rabbit anti-human phospho-STAT3 (Ser727) 86 1:1,000 Cell Signalling
Mouse anti-human phospho-STAT3 (Tyr705) 86 1:1,000 Cell Signalling
Mouse anti-human/dog PKB 60 1:250 BD Biosciences
Rabbit anti-human phospho-PKB (Thr308) 60 1:1,000 Cell Signalling
Rabbit anti-human Erk1/2 42/44 1:1,000 Cell Signalling
Rabbit anti-human phospho-ERK1/2 (Thr202/Tyr204) 42/44 1:1,500 Cell Signalling
Rabbit anti-human p38-MAPK 38 1:500 Abcam
Rabbit anti-human phospho-p38-MAPK (Thr180/Tyr182) 38 1:1,000 Abcam
Mouse anti-human/dog Beta-actin (pan Ab-5) 42 1:2,000 Neomarkers
Table 1: Nucleotide Sequences of Dog-Specific Primers for Real-Time Quantitative PCR
Gene Primer Sequence (5'-3') Tm (°C) Product size (bp) Accession number
GAPDH Forward TGT CCC CAC CCC CAA TGT ATC 58 100 AB038240
Reversed CTC CGA TGC CTG CTT CAC TAC CTT
HPRT Forward AGC TTG CTG GTG AAA AGG AC 56 100 L77488 /
Reversed TTA TAG TCA AGG GCA TAT CC L77489
HGF Forward AAA GGA GAT GAG AAA CGC AAA CAG 58 92 BD105535
Reversed GGC CTA GCA AGC TTC AGT AAT ACC
c-MET Forward TGT GCT GTG AAA TCC CTG AAT AGA AATC 59 112 AB118945
Reversed CCA AGA GTG AGA GTA CGT TTG GAT GACPublish with BioMed Central    and   every 
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